Muhlenkamp & Co’s Gilead Sciences GILD Stock Holding History

Muhlenkamp & Co’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$170K	Hold	2,200	–	–	0.07%	32
2018 Q2	$156K	Hold	2,200	–	–	0.06%	36
2018 Q1	$166K	Sell	2,200 -22,500	-91%	-$1.79M	0.06%	36
2017 Q4	$1.77M	Sell	24,700 -900	-4%	-$68.3K	0.52%	34
2017 Q3	$2.07M	Hold	25,600	–	–	0.65%	31
2017 Q2	$1.81M	Sell	25,600 -3,000	-10%	-$200K	0.57%	34
2017 Q1	$1.94M	Buy	28,600 +13,800	+93%	+$970K	0.6%	34
2016 Q4	$1.06M	Buy	14,800 +7,300	+97%	+$543K	0.33%	39
2016 Q3	$593K	Buy	7,500 +4,300	+134%	+$349K	0.22%	38
2016 Q2	$267K	Hold	3,200	–	–	0.1%	46
2016 Q1	$294K	Buy	+3,200	New	+$289K	0.12%	40

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Muhlenkamp & Co's GILD Position: Q1 2021 in Review

Muhlenkamp & Co sold out of Gilead Sciences (GILD) in Q1 2021, closing a stake of 50,803 shares — an estimated $2.96M sold.

Muhlenkamp & Co first reported a position in GILD in Q2 2013 and held it in 29 quarters. The position peaked at $25.6M in Q2 2015. 1,567 funds tracked by Wall St. Rank hold GILD as of Q1 2021.

Muhlenkamp & Co reported no remaining Gilead Sciences position as of Q1 2021 after selling out during the quarter.
Muhlenkamp & Co sold 50,803 Gilead Sciences shares in Q1 2021, an estimated $2.96M.
Muhlenkamp & Co first reported a position in Gilead Sciences in Q2 2013 and held it in 29 quarters.
Muhlenkamp & Co's Gilead Sciences position peaked at $25.6M in Q2 2015.
1,567 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2021.

Based on Muhlenkamp & Co's 13F filing for Q1 2021, filed 18 Aug 2021.